Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 3 , Pages 371-373, March 2006

Selecting an Antidepressant for the Treatment of Pediatric Depression

Dr. Kratochvil is with the Department of Psychiatry, University of Nebraska Medical Center, Omaha; Dr. Vitiello is with the National Institute of Mental Health, Bethesda, MD; Dr. Brent is with University of Pittsburgh Medical Center, Pittsburgh; Dr. Bostic is with Massachusetts General Hospital, Boston; and Dr. Naylor is with University of Illinois at Chicago

Accepted 2 November 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.

 This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.

 Disclosure: Dr. Kratochvil has received grant support from, is a consultant to, and/or member of the speaker's bureau of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Bostic has received grant support and/or honoraria from Abbott, Forest, GlaxoSmithKline, Eli Lilly, and Pfizer. The other authors have no financial relationships to disclose.

PII: S0890-8567(09)62029-3

doi:10.1097/01.chi.0000197029.87378.1c

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 3 , Pages 371-373, March 2006

Article Tools